natgillin/translations-raw huggingface dataset:
Furthermore, this allows the cover to be made transparent allowing for visual inspection of the content of the container, provided the container is also transparent. 
Osim toga, to omogućuje da se pokrov izradi proziran i da se tako sadržaj spremnika može kontrolirati očno, pod uvjetom da je i spremnik također proziran.
A compound according to claim 1 which is selected from the group consisting of: 
Spoj prema zahtjevu 1, naznačen time da je odabran iz skupine koju čine:
A combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 10 and one or more agents selected from carbamazepine, olanzapine, quetiapine, verapamil, lamotrigine, oxcarbazepine, risperidone, aripiprazole, ziprasidone and lithium. 
Kombinacija spoja s formulom (I) ili njegove farmaceutski prihvatljive soli kako je zatraženo u bilo kojem od zahtjeva 1 do 10 i jednog ili više sredstava odabranih od karbamazepina, olanzapina, kvetiapina, verapamila, lamotrigina, okskarbazepina, risperidona, aripiprazola, ziprasidona i litija.
A compound of formula or a pharmaceutically acceptable salt thereof, wherein: X1= 
Spoj ili njegova farmaceutski prihvatljiva sol sukladno zahtjevu 1, gdje je spoj: Å a
detecting the presence or absence of DNA amplified in step (b), wherein the presence or absence of amplified DNA reflects the presence or absence, respectively, of hypermethylated target DNA in the sample. 
(c) otkrivanje prisutnosti ili odsutnosti DNA amplificirane u koraku (b), pri čemu prisutnost ili odsutnost amplificirane DNA povlači za sobom prisutnost ili odsutnost hipermetilirane ciljne DNA u uzorku.
The method according to claim 1, wherein the aqueous medium, after the addition of the cPCC in an amount of at least 10 g/L aqueous medium, has: 
Upotreba u skladu s bilo kojim od patentnih zahtjeva 1 do 14, naznačena time što vodeni medij, nakon dodavanja cPCC u količini od najmanje 10 g/l u vodeni medij, ima
The process of claim 1, wherein the Lewis acid is selected from the group consisting of zinc chloride, zinc bromide, ferric chloride, and ferric bromide. 
Postupak prema patentnom zahtjevu 1, gdje je Lewis-ova kiselina izabrana iz grupe koju čine cinkov klorid, cinkov bromid, želljezni (III) klorid i željezni (IID) bromid.
The device of claim 8, wherein the device further includes a clip affixed to the device, wherein the clip is configured to clip the device onto an object. 
Uređaj prema zahtjevu 1 ili postupak prema zahtjevu 5, naznačen time, da uređaj nadalje obuhvaća dodatni otvor, pri čemu je dodatni otvor načinjen kao sastavni dio donjeg odsječka uređaja.
The immunogenic composition of claim 3 or 4 comprising N. meningitidis serogroup A capsular saccharide (MenA). 
Imunogeni pripravak u skladu s patentnim zahtjevom 3 ili 4, naznačen time što najmanje dva dodatna konjugata bakterijskih saharida sadrže saharid iz kapsule bakterije N. meningitidis seroskupina Y (MenY).
LCMS are recorded on an Agilent 1100 LC system with a Waters Xterra MS C18 4.6×100 5 uM column, eluting with 5-95% 10 mM aqueous ammonium bicarbonate in acetonitrile over 10 minutes, with negative ion electrospray ionization or 5-95% water+0.1% TFA in acetonitrile with positive ion electrospray ionization. 
LCMS su zapisani na sistemu Agilent 1100 LC sa stupcem Waters Xterra MS C18 4,6 x 100 5 uM, ispirući s 5-95%-tnim 10 mM vodenim amonijevim bikarbonatom u aceto-nitrilu kroz 10 minuta, ionizacijom s negativnim ionskim elektrosprejem ili 5-95% vode + 0,1% TFA u acetonitrilu ionizacijom s pozitivnim ionskim elektrosprejem.
Use of a combination of a renin inhibitor and an efflux protein inhibitor, wherein the renin inhibitor is a δ-amino-Y-hydroxy-w-aryl-alkanoic acid amide derivative or a pharmaceutically acceptable salt thereof for the manufacture of a medicament, wherein the efflux protein inhibitor improves the bioavailability of a renin inhibitor, and wherein the efflux protein inhibitor is a MDR1 inhibitor. 
Uporaba kombinacije inhibitora renina i inhibitora istjecanja proteina, pri čemu je inhibitor renina derivat amida δ-amino-Y-hidroksi-w-aril-alkanoične kiseline ili njegova farmaceutski prihvatljiva sol, naznačena time, da se koristi za pripravu lijeka, pri čemu inhibitor istjecanja proteina poboljšava bioraspoloživost inhibitora renina, te pri čemu inhibitor istjecanja proteina je inhibitor MDR1.
The dipeptide was dissolved in 10 mL 20% TFA/dichloromethane, and stirred at room temperature for 2 hours, then the crude product isolated by removal of volatiles under vacuum. 
Dipeptid je otopljen u 10 ml 20% TFA/diklormetan, i miješana kod sobne temperature 2 sata, nakon čega je kruti produkt izoliran uklanjanjem hlapivog pod vakuumom..
FIG. 9: schematic representation of a system (10) for preparing liquid products according to the invention, and comprising at least two single-portion packages (1, 1 ′) including different flow distribution elements (4, 4 ′). 
Postupak priprave tekućeg proizvoda, obuhvaća korake: - pružanje stroja (11) uključujući barem jedan uređaj za ekstrakciju (12) prilagođen za pružanje protoka tekućine pod tlakom u jednodijelno pakiranje (1, 1?)
The grooming tool of claim 5 wherein the head includes a locking tab arrangement constructed and arranged to releasably lock the blade carrier in at least the first position and the second position. The grooming tool of claim 6 wherein: the blade carrier includes first and second grooves therein; and 
Alat za njegu (10) u skladu s patentnim zahtjevom 3, naznačen time što glava (14) ima sklop zabravljujućih jezičaca (86) takve konstrukcije i smještaja da odvojivo zabravljuju nosač oštrica (30) u najmanju ruku prvom položaju i drugom položaju.
PG is a protecting group selected from the group consisting of an acyl protecting group and a urethane protecting group, for example wherein PG is a protecting group selected from the group consisting of formyl, acetyl, succinyl, methoxysuccinyl, tert -butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), and fluorenylmethoxycarbonyl (Fmoc). 
punitelj je izabran iz grupe koju čine celuloza u prahu, mikrokristalna celuloza, silicificirana mikrokristalna celuloza, mikrokristalna celuloza sa niskim sadržajem vlage, natrijev škrob glikolat, preželatinizirani škrob, i njihove smjese, poželjno gdje je punitelj izabran iz grupe koju čine mikrokristalna celuloza sa niskim sadržajem vlage, natrijev škrob glikolat, preželatinizirani škrob, i njihove smjese; i/ili
VL1-L1-VL2-L2-CL [I] and two polypeptide chains have a structure represented by the formula: 
VLr-Li-Vre-L-C [1] i dva polipeptidna lanca imaju strukturu predstavljenu s formulom:
a protein-binding segment that interacts with said chimeric Cas9 protein, wherein the protein-binding segment comprises two complementary stretches of nucleotides that hybridize to form a double stranded RNA (dsRNA) duplex, wherein said contacting is in vitro or in a cell ex vivo. 
segment koji se veže na proteine koji međudjeluje s polipeptidom Cas9, gdje segment koji se veže na proteine sadrži dva komplementarna odsječka nukleotida koji hibridiziraju kako bi tvorili dvolančani RNA (dsRNA) dupleks, gdje je ciljana DNA prisutna u jednostaničnom eukariotskom organizmu, životinjskoj stanici ili biljnoj stanici, gdje je navedeno modificiranje cijepanje ciljane DNA, gdje: navedeno stavljanje u kontakt se provodi in vitro ili u stanici ex vivo; i/ili
A process for preparing Compound 6: which process comprises preparing Compound 10 by the process according to any one of claims 2 to 10 and converting Compound 10 to Compound 6. 
Postupak za pripremu spoja 6: [image] koji sadrži pripremu spoja 10 pomoću postupka prema bilo kojem od patentnih zahtjeva 2 do 10 i konverziju spoja 10 u spoj 6.
The method of claims 1-14, wherein total aluminium content in the vaccine is 200-1000µg, 300-900µg, 400-800µg, 500-700µg or around or exactly 630µg Al3+ per 0.5mL dose. 
Postupak u skladu s patentnim zahtjevima 1-14, naznačen time što je ukupan sadržaj aluminija u cjepivu 200-1000 ug, 300-900 ug, 400-800 ug, 500-700 ug ili otprilike ili točno 630 ug AP* na 0,5 ml doze.
a composition suitable for control of diseases caused by phytopathogens comprising (A) a compound of formula I 
Pripravak koji je pogodan za nadzor bolesti uzrokovanih fitopatogenim organizmima uključujući (A) spoj formule I
In a preferred embodiment, the inert gas is N2 or Ar and the reactive species is O2. 
Postupak prema zahtjevu 31, pri čemu je inertni plin N, ili AT 1 reaktivna vrsta je Oz.
pH and conductivity were checked, and washing continued if the parameters of the column's effluent were out of target values, pH 6.0±0.2, conductivity 45±15 µS/cm. 
pH i provodljivost su bili provjereni, a s ispiranjem je nastavljeno ukoliko su parametri protoka iz kolone bili izvan ciljnih vrijednosti, pH 6.0::0.2, provodljivost 45+15 uS/em.
The system of claim 7 wherein said controller (16) is operable to automatically allow containers from a previously rejected mold cavity to continue for further processing. 
Sustav u skladu s patentnim zahtjevom 7, gdje navedeni uređaj za kontrolu (16) radi tako da automatski omogućuje da spremnici iz prethodno odbačene šupljine kalupa idu na daljnju obradu.
adjusting the pH of the eluate from the Fractogel EMD SE Hi-Cap cation exchange column from step e) to about pH 3.5 ± 0.1 for viral inactivation; 
podešavanje pH eluata iz Fractogel EMD SE Hi-Cap kolone za kationsku izmjenu iz koraka e) do oko pH 3.5 ± 0.1 radi inaktivacije virusa;
Our clinical studies were carried out with 14 patients, presenting chronic pain syndrome for at least three months. 
Naše kliničke studije provedene su sa 14 pacijenata, koji su predstavljali sindrom kronične boli kroz najmanje tri mjeseca.
Hc is selected from the group of tetrahydropyranyl, tetrahydrofuranyl, piperidinyl, pyrrolidinyl; 
Hc je odabran iz skupine koju čine: tetrahidropiranil, tetrahidrofuranil, piperidinil, pirolidinil;
The dispensing closure according to Claim 1, characterized in that the separable lock (7) is fitted with an attachment ring. 
Zatvarač sustava razdjeljivanja prema zahtjevu 1, naznačen time, da je odvojivi zapor (7) pričvršćen pomoću priključnog prstena.
A process for the preparation of a compound of formula (V), said process comprising the step of: 
(V) naknadno odcijepi, u pogodnom otapalu, čime se dobije spoj formule (VID) O
is optionally substituted C1-C12 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C2-C12 alkenyl, optionally substituted C2-C12 alkynyl, optionally substituted aryl, or optionally substituted heteroaryl; 
je izborno supstituirani C1-C12 alkil, izborno supstituirani C3-C8 cikloalkil, izborno supstituirani C2-C12 alkenil, izborno supstituirani C2-C12 alkinil, izborno supstituirani aril ili izborno supstituirani heteroaril;
The pharmaceutical formulation of claim 12, wherein the siRNA has a sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4. 
Farmaceutska formulacija u skladu s patentnim zahtjevom 12, pri čemu siRNA ima sekvencu izabranu iz SEQ ID NO: 1, SEQID NO: 2, SEQID NO: 31 SEQ ID NO: 4.
The antibody according to any one of claims 1 and 2, characterized in that it is a full length IgG1, IgG2, IgG3, IgG4, IgD, IgA, IgE, or IgM antibody. 
Protutijelo sukladno patentnom zahtjevu 1, karakterizirano time da je u punoj duljini IgG1, IgG2, IgG3, IgG4, IgD, IgA, IgE, ili IgM protutijelo.
5% Aqueous sodium hydrogencarbonate solution (625 mL) was then added dropwise at 20 - 45 °C. The batch was seeded and aged at 20 - 30 °C for 1-2 h. 
5% vodena otopina natrij hidrogenkarnonata (625 mL) je zatim dodavana u kapima, na 20-45 *C za 1-2 h.
This embodiment can be represented by Formula (Io) as illustrated below: 
Taj oblik se može prikazati Formulom (Io) prikazanom dolje:
to generate a compound of formula IX in which formulae 
(VIII) kako bi se dobilo spoj formule IX
activating the compound of Formula LXI to a compound of Formula LXII; 
Formula LXI aktiviranje spoja Formule LXI u spoj Formule LXII:
The wind turbine according to claim 6, including whirl triggers (14) having only four surfaces are arranged in a common plane as the efficiency enhancers (13). 
Vjetrena turbina u skladu s patentnim zahtjevom 3, naznačena time što su okidači vrtloženja (14) omeđeni s četiri površine smješteni u istoj ravnini kao navedeni poboljšivači djelotvornosti (13).
The variant ActRIIB protein of claim 1 or claim 2, wherein the protein comprises an amino acid sequence beginning at an amino acid corresponding to any of amino acids 22-25 of SEQ ID NO: 2 and ending at an amino acid corresponding to any of amino acids 129-134 of SEQ ID NO: 2. 
Varijantni ActRIIB protein iz bilo kojeg od prethodnih zahtjeva, naznačen time, što protein sadrži aminokiselinsku sekvencu koja počinje aminokiselinskom reziduom koja odgovara nekoj od amino-kiselina 22-25 SEQ ID NO:2 i završava se amino-kiselinom koja odgovara nekoj od amino-kiselina 131, 133, ili 134 SEQ ID NO:2.
A method of producing an immunoconjugate comprising: culturing a host cell which has been transformed by an isolated nucleic acid comprising a sequence encoding an antibody or antigen binding fragment thereof wherein the antibody comprises a heavy chain comprising an amino acid sequence of SEQ ID NO:87 and a light chain comprising an amino acid of SEQ ID NO:88; 
Imunokonjugat prema bilo kojem od zahtjeva 22 do 28, naznačen time da protutijelo sadrži teški lanac koji sadrži sekvencu SEQ ID NO:87 ili sekvencu koja je s njom barem 85% identična i laki lanac koji sadrži sekvencu SEQ ID NO:88 ili sekvencu koja je s njom barem 85% identična.
Fragrances are aromatic substances which can impart an aesthetically pleasing aroma to the sunscreen composition. 
Mirisi su aromatske tvari koje mogu dati estetski ugodnu aromu pripravku sredstva za zaštitu od sunca.
The fibre of claim 17, wherein said fibre comprises a highly aligned or continuous micro-structure which provides said fibre with a minimal tensile strength of 20cN/tex. 
Vlakno prema zahtjevu 17, naznačeno time da navedeno vlakno sadrži vrlo poravnatu ili neprekidnu mikrostrukturu koja daje navedeno vlakno sa najmanjom vlačnom čvrstoćom od 20cN/tex.
The bone plate system of claim 1, further comprising a relief cut (2165) that includes sections that each incline inward from the upper surface (1137) of the bone plate (1100). 
Sustav u skladu s patentnim zahtjevom 1, naznačen time, da dodatno sadrži pločicu za kosti koja ima gornju površinu, donju površinu i veći broj otvora koji se protežu od gornje površine do donje površine.
In an embodiment, the intra-granular fraction (i.e. granules) may for example comprise up to 50% of the total weight of the formulation, e.g. from 30% to 50% by weight of the formulation. 
Metoda iz zahtjeva 1. ili zahtjeva 2., pri čemu intragranularna frakcija čini 50 % ukupne težine formulacije i pri čemu ekstragranularna frakcija čini 50 % ukupne težine formulacije.
is selected from the group consisting ofH and -C1-C2 alkyl; 
je izabran iz grupe koju čine H i -C1-C2 alkil;
The sliding door system of claim 3, wherein the opening exposed is of variable size, and is sizable with respect to one or more of the vehicle's wheelbase and track. 
Sustav kliznih vrata prema zahtjevu 3, pri čemu nastali otvor (620) može biti raznih veličina koje se mogu podesiti s obzirom na jedan ili više međuosovinskih razmaka kotača vozila i tračnica.
In case the concentration of SDS is not known, however, it can be measured using conventional assay techniques, either performed on the material as a whole or on a sample of the material. 
U slučaju da koncentracija SDS nije poznata, usprkos tome ona se može mjeriti koristeći uobičajene analitičke tehnike, bile one izvedene na materijalu u cjelini ili na uzorku materijala.
A method as defined in any one of claims 6 to 8 wherein the binding agent is an antibody. 
Postupak kako je definirano u zahtjevu 5 ili zahtjevu 6, naznačen time što je sredstvo za vezanje protutijelo.
Such a spraying system uses a substantial amount of water per unit forage. 
Takav sustav raspršivanja koristi značajne količine vode po jediničnoj količini krupne stočne hrane.
As a compound represented by the formula (I) of the present invention, 
Uporaba, naznačena time, da se koristi spoj prikazan formulom (I)
The present invention provides: a pharmaceutical composition for oral administration comprising (1) a modified release portion comprising tamsulosin or a pharmaceutically acceptable salt thereof, and (2) an immediate release portion comprising solifenacin or a pharmaceutically acceptable salt thereof and a hydrophilic substance; 
Tableta za oralnu primjenu koja sadrži (1) sloj koji predstavlja dio s prilagođenim oslobađanjem i koji sadrži tamzulozin ili njegovu farmaceutski prikladnu sol, i polimer koji formiran hidrogel, 1 (2) sloj koji predstavlja dio s trenutnim otpuštanjem i koji sadrži solifenacin ili njegovu farmaceutski prikladnu sol 1 barem jednu hidrofilnu tvar iz skupine koju čine D-manitol, maltoza, polietilen glikol i polivinilpirolidon.
Said adhesive comprised the reaction product of diphenylmethane diisocyanate with polypropylene glycol. 
Navedeno ljepilo je sadržavalo proizvod za reakciju od diizocijanata difenilmetana s propilen glikolom.
The mechanism of action of statin drugs has been elucidated in some detail. 
Mehanizam djelovanja statina detaljno je razjašnjen.
The composition according to claim 21, wherein said effective amount is about 0.001-50 mg/kilogram of said cells, tissue, organ or animal. 
pri čemu je navedena učinkovita količina oko 0,001-50 mg/kilogramu navedenih stanica, tkiva, organa ili životinja;
The ether layer was removed and the aqueous layer extracted with ether (2 X 200 ml.l. 
Eterski sloj se odvoji i vodeni sloj se ekstrahira sa eterom (2 x 200 ml.).
The pharmaceutical composition according to claim 4, comprising a stereoisomeric mixture of compounds according to formulae II, III, IV and/or V. 
Farmaceutski pripravak u skladu s prethodnim patentnim zahtjevom, naznačen time što sadrži stereoizomernu smjesu spojeva formula II, III, IV i/ili V.
The method of claim 1, wherein the first detector is present within a conjugate region of the surface and wherein the conjugate region does not overlap with the test region of the surface. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je prvi detektor imobiliziran na konjugatnom području površine i gdje se konjugatno područje ne preklapa s ispitrvanim područjem površine.
"Alkoxy" includes an optionally substituted straight chain or branched alkyl group with a terminal oxygen linking the alkyl group to the rest of the molecule. 
"Alkoksi" uključuje eventualno supstituirani ravni lanac ili razgranatu alkilnu skupinu s terminalnim kisikom povezanim s alkilnom skupinom na ostatak molekule.
R4y is hydrogen, C1-4 alkyl, C1-4 fluoroalkyl, C6-10 ar(C1-4)alkyl, the aryl portion of which may be optionally substituted, or an optionally substituted 5- or 6-membered aryl, heteroaryl, or heterocyclyl ring; or 
y je vodik,C1-4 alkil,C1-4 fluoroalkil, C6-10ar(C1-4)alkil, čiji aril dio može biti opcijski supstituiran, ili opcijski supstituirani 5- ili 6-člani aril, heteroaril ili heterociklil prsten; ili
hydrogenating the compound of Formula LIX to give a compound of Formula LX; 
Formula LIX hidrogeniranje spoja Formule LIX, čime se dobiva spoj Formule LX:
The compound according to paragraph 2, wherein D is straight or branched (C3-C5)alkylene. 
Spoj prema zahtjevu 1, naznačen time da D je ravnolančani ili razgranati (C3-Cs)alkilen.
It was initially identified as an enzyme able to phosphorylate and hence inhibit glycogen synthase. 
Najprije je identificirana kao enzim koji fosforilira, a time 1 inhibira glikogen-sintazu.
It has furthermore been found that the removal of polycyclic compounds, cholesterol, and/or EDCs from an aqueous medium is especially effective, when the surface-reacted calcium carbonate is used in combination with activated carbon. 
Postupak prema zahtjevu 18, pri čemu, ako voda koju treba pročistiti sadrži barem jedan spoj izabran od policikličnih spojeva, kolesterola, i/ili spojeva koji izazivaju endokrine poremećaje, površinski-reagirani prirodni kalcij karbonat se koristi u kombinaciji sa aktivnim ugljenom.
wherein R7, R8, and R9 are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocyclyl; 
gdje R7, R8 i R9 su nezavisno izabrani iz grupe koja se sastoji od vodika, izborno supstituiranog alkila, izborno supstituiranog alkenila, izborno supstituiranog alkinila, izborno supstituiranog heteroalkila, izborno supstituiranog arila, izborno supstituiranog heteroarila, izborno supstituiranog cikloalkila i izborno supstituiranog heterociklila;
reaction (O1-reac) is a reaction of compound of formula (XXIII) with water and with a compound (O1-comp); 
Kod reakcije (O-reak.) radi se o reakciji spoja formule (XXIII) s reagensom (O-reag.); Zan
X is a methylene group, wherein the methylene group may be substituted with a methyl group; 
X je metilenska skupina; pri čemu metilenska skupina može biti zamijenjena sa metilnom skupinom;
Preparing a cell suspension from uterine cervix tissue obtained by exfoliation of the uterine cervix, 
pripravu suspenzije stanica iz tkiva vrata maternice dobivenog eksfolijacijom vrata maternice,
Where the composition is in the form of a soft gelatine capsule any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be considered, for example aqueous gums, celluloses, silicates or oils, and are incorporated in a soft gelatine capsule. 
Za pripravak u obliku meke želatinske kapsule mogu se koristiti svi farmaceutski nosači koji se rutinski koriste za izradu disperzija ili suspenzija, na primjer gume u otopini, celuloze, silikati ili ulja 1 ugrađuju se u meke želatinske kapsule.
Results are shown in Figure 10, and Figure 13 superimposes the turbidity results on the SDS removal profile of Figure 12. 
Rezultati su prikazani na Slici 10, a Slika 13 superponira rezultate zamućenosti na profilu odstranjivanja SDS Slike 12.
The method of claim 3, wherein the agent with a2 adrenergic receptor agonist activity is selected from phenylpropanolamine, propylhexadrine, amphetamine, dextroamphetamine, ephedrine, epinine, ethylnorepinephrine, levarterenol, lofexidine, methamphetamine, a-methylnorepinephrine, methylphenidate, mivazerol, moxonidine, norepinephrine, norphenylephrine, pemoline, tizanidine and combinations thereof. 
Agonist za uporabu u skladu sa zahtjevom 3, naznačen time što je sredstvo s aktivnošću agonista alfa 2 adrenergijskog receptora odabrano od fenilpropanolamina, propilheksedrina, amfetamina, dekstroamfetamina, efedrina, -epinina, < etilnorepinefrina, = levarterenola, lofeksidina, metamfetamina, alfa-metilnorepinefrina, metilfenidata, mivazerola, moksonidina, norepinefrina, norfenilefrina, pemolina, tizanidina i njihovih kombinacija.